Geneos to Highlight Clinical and Supportive Pharmacodynamic Data From Personalized Therapeutic Cancer Vaccine Phase 1b/2a Clinical Trial at SITC Conference
Encouraging Safety and Efficacy Data from Ongoing GT-30 Study in Second-Line HCC
Geneos Therapeutics Secures $17 Million in Series A2 Financing to Advance Personalized Cancer Immunotherapy Platform
Geneos expands its Phase Ib/IIa clinical trial in lead indication for treating patients with advanced hepatocellular carcinoma
Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine Program
Geneos Therapeutics announced positive preliminary results of its ongoing first-in-human trial.
VGXI and Geneos Therapeutics Expand Partnership for Personalized Cancer Immunotherapies
Texas-based GMP Plasmid CDMO VGXI, Inc. and Geneos Therapeutics, Inc. Expand their Clinical Manufacturing Supply Agreement in Support of Geneos’ Ongoing GT-30 Phase Ib/IIa Clinical Trial for advanced hepatocellular carcinoma (HCC)
Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs
Geneos Therapeutics has closed its Series A1 round, raising $12 million in financing.
VGXI Enables Rapid GMP DNA Manufacturing Timeline for Geneos Therapeutics Personalized Cancer Immunotherapy
VGXI, Inc., Geneos Therapeutics’ CDMO partner, completes manufacturing of first GMP Lot under Clinical Manufacturing Supply Agreement.
Geneos Personalized Neoantigen-Targeting Vaccine (GNOS-PV02) to be Utilized in Innovative GT-30 Hepatocellular Carcinoma Trial
Geneos Therapeutics announced that its personalized neoantigen-targeting vaccine, GNOS-PV02 (based on its proprietary GT-EPIC™ platform), will be evaluated in a clinical trial for patients with advanced Hepatocellular Carcinoma (HCC).
Texas Based CMO VGXI and Geneos Therapeutics Establish Supply Agreement for Production of GT-EPIC-Based Personalized Cancer Therapeutics
VGXI and Geneos Therapeutics have entered into a long-term master supply agreement to establish small-scale and rapid turnaround production services ideally suited for the personalized therapy approach.
Geneos Therapeutics Secures $10.5 Million in Series A Financing to Develop the Next Generation of Neoantigen-Targeting Cancer Immunotherapies
Geneos has Licensed Immunotherapy Platform from Inovio Pharmaceuticals for Developing Personalized Cancer Treatments Santé Ventures Leads Financing with Additional Investment from Inovio Pharmaceuticals PLYMOUTH MEETING, PA – February 21, 2019 – Geneos Therapeutics announced today that it has closed its Series A round raising $10.5 Million in financing. This funding will launch its operations as … Read more